ChemoCentryx, Inc.
CCXI
CCXI was delisted on the 19th of October, 2022.
140 hedge funds and large institutions have $761M invested in ChemoCentryx, Inc. in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 43 increasing their positions, 52 reducing their positions, and 28 closing their positions.
32% more call options, than puts
Call options by funds: $117M | Put options by funds: $88.8M
27% more capital invested
Capital invested by funds: $598M → $761M (+$163M)
4% less funds holding
Funds holding: 146 → 140 (-6)
17% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 52
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$40.1M |
| 2 |
PA
Perceptive Advisors
New York
|
+$8.57M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.47M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.03M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$6.01M |
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$51.1M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$7.34M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$5.66M |
| 4 |
D.E. Shaw & Co
New York
|
-$5.22M |
| 5 |
Jane Street
New York
|
-$4.06M |
CCXI Hedge Fund Activity: Q3 2021 in Review
140 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q3 2021, worth a combined $761M — up 27% from $598M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of CCXI and 23 opened new positions — a net loss of 5 holders — while 52 trimmed existing stakes and 43 added.
The largest buyer was Wasatch Advisors, opening a new position worth an estimated $40.1M. The largest seller was RA Capital Management, cutting an estimated $51.1M.
- 140 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q3 2021, down from 146 in Q2 2021.
- Funds reported $761M of ChemoCentryx, Inc. stock for Q3 2021, up 27% quarter-over-quarter.
- 23 funds opened new ChemoCentryx, Inc. positions in Q3 2021 and 28 closed out, a net change of -5 holders.
- The largest ChemoCentryx, Inc. buyer in Q3 2021 was Wasatch Advisors, an estimated $40.1M added.
- The largest ChemoCentryx, Inc. seller in Q3 2021 was RA Capital Management, an estimated $51.1M sold.
Based on aggregated 13F filings for Q3 2021.